BOT 0.00% 38.0¢ botanix pharmaceuticals ltd

Ann: Phase 2a Study Shows BTX 1801 Eradicates S. Aureus, page-941

  1. 40 Posts.
    lightbulb Created with Sketch. 44
    nice one. unfortunately the ASX no longer allow biotechs to include comparisons in trial data announcements. If they did, it's highly likely BOT would have included that Mupirocin has a current known efficacy of about 60%, and some hospitals are seeing resistance levels of more than 90% to that treatment. Hoping they are allowed to include this in their next investor presentation.
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.